Everolimus Tablet
Product Images NDC 51991-985

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 51991-985). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Everolimus 01)

Chemical structure diagram of Everolimus, the active ingredient in Everolimus tablets. The image shows the molecular structure with rings, bonds, and functional groups characteristic of this compound.*

FDA Label Image

Figure 1 (Everolimus 02)

A line graph comparing eGFR (mL/min/1.73 m2) over multiple visit windows between two treatment groups: one receiving Everolimus (EVR) and a TAC control group. The x-axis denotes visit windows from screening through 24 months, and the y-axis shows eGFR values ranging from 60 to 110. Data points include error bars for variability.*

FDA Label Image

Principal Display Panel (0.25 mg Tablet Blister Pack Carton)

Flat layout of Everolimus Tablets carton label showing 0.25 mg strength per tablet. The label indicates oral tablets with a 60-tablet count, dispensed with a medication guide. The manufacturer is Natco Pharma Limited, India, and the distributor is Breckenridge Pharmaceutical, Inc., Berlin, CT. Storage instructions and warnings appear on the label.*

FDA Label Image

Principal Display Panel (0.25 mg Tablet Blister Pack)

Packaging label for Everolimus Tablet 0.25 mg distributed by Breckenridge Pharmaceutical, Inc., Berlin, CT. The label includes NDC 51991-379-99, manufacturing information from Natco Pharma Ltd., Kothur, India, and a barcode. This label is designed for multiple tablet units, each with identical print and barcode.*

FDA Label Image

Principal Display Panel (0.5 mg Tablet Blister Pack Carton)

Packaging label for Everolimus Tablets 0.5 mg per tablet by Breckenridge Pharmaceutical, Inc. The carton holds 60 tablets distributed in 6 blister cards of 10 tablets each. The label includes dosage instructions to see the package insert, storage conditions, warnings to keep out of children's reach, manufacturing and distribution details, a barcode, and batch information.*

FDA Label Image

Principal Display Panel (0.5 mg Tablet Blister Pack)

Labels for Everolimus Tablet 0.5 mg show distribution by Breckenridge Pharmaceutical, Inc., Berlin, CT, and manufacturing by Natco Pharma Ltd., Kothur, India. Each label includes the NDC 51991-380-99, lot number, expiration date, and a barcode. Issued April 2021, these labels are formatted in green and black text on a white background.*

FDA Label Image

Principal Display Panel (0.75 mg Tablet Blister Pack Carton)

Packaging label for Everolimus Tablets, 0.75 mg per tablet, oral tablet form. The label shows the product name and strength prominently, with NDC 51991-381-60. The carton contains 60 tablets packaged as 6 blister cards of 10 tablets each. Manufacturer is Natco Pharma Limited, India, with distribution by Breckenridge Pharmaceutical, Inc., Berlin, CT. The label includes storage instructions and a medication guide notice.*

FDA Label Image

Principal Display Panel (0.75 mg Tablet Blister Pack)

Packaging label for Everolimus Tablet 0.75 mg by Breckenridge Pharmaceutical, Inc., distributed in Berlin, CT. The label includes the NDC code 51991-381-99, details on manufacturing by Natco Pharma Ltd. in India, barcode, and space for batch number and expiration date. The label is repeated multiple times formatted for printing and cutting.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.